Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: Logain Ablar who wrote (503)	3/24/2001 11:45:39 PM
From: Cacaito	Respond to of 656

Near Competition is Amgen's Anakinra, plus a bunch of others. But, Imnx is way ahead in RA. Imnx could be finally digested by AHP (like Centocor, Agouron, Sugen were in the recent past), and it could command a quick premiun. Inhale Therapeutics and others are advancing technology for delivery of insulin and other large molecules/proteins via lung inhalation. Embrel could go that way in delivery. Alkermes delivery via slow release polypedtide envelope is a future way to deliver this type of protein. Growth hormone is a complex molecule and is now approved combining Genentech origin hormone plus Alkermes slow release technology. Embrel could go that way. Emisphere is working on phase III heparin in a polypetide envelope that is slowly digested in the gastrointestinal tract and provide accurate amounts of heparin. This oral technique (and others are working in similar products for Insulin/Calcitonin) is another way Embrel could go.